Welcome to our dedicated page for Ocular Therapeut SEC filings (Ticker: OCUL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech filings can feel like decoding a clinical protocol—especially when Ocular Therapeutix’s latest 10-K runs hundreds of pages of trial data, cash-runway tables, and FDA milestones. If you have ever Googled “Ocular Therapeutix SEC filings explained simply” or struggled to locate safety endpoints buried deep in an exhibit, this page is built for you.
Stock Titan’s AI reads every new Ocular Therapeutix quarterly earnings report 10-Q filing, Form 8-K material events explained updates, and proxy statement executive compensation tables the moment they hit EDGAR. Our engine produces concise plain-English summaries, highlights pivotal Phase 3 results, and flags liquidity changes—so understanding Ocular Therapeutix SEC documents with AI takes minutes, not hours. Real-time alerts push Ocular Therapeutix Form 4 insider transactions real-time to your dashboard, letting you monitor executive stock transactions Form 4 alongside trial announcements.
Here’s what you can do on this page:
- Track Ocular Therapeutix insider trading Form 4 transactions and option grants before broader market reaction.
- Dive into Ocular Therapeutix earnings report filing analysis without poring over accounting footnotes.
- Access the Ocular Therapeutix annual report 10-K simplified to check cash runway and royalty obligations.
- Set alerts for each Ocular Therapeutix 8-K material events explained, from FDA feedback to partnership deals.
Whether you follow retinal drug developers or just need a clear view of risk factors, our comprehensive coverage—every S-1, 10-Q, 10-K, 4, and DEF 14A—keeps you informed in real time. No more hunting through EDGAR; the critical disclosures investors care about arrive already summarized, searchable, and connected to live market data.
Ocular Therapeutix (OCUL) filed a Form 3 disclosing the initial beneficial ownership of its newly appointed Chief Business Officer, Namrata Saroj. The filing reports direct ownership of 200,000 unvested restricted stock units (RSUs) that will vest in three equal annual installments beginning on the first anniversary of her start date.
Derivative holdings include 466,000 stock options spread across three grants: 50,000 options already fully vested at an exercise price of $9.95 expiring 02/27/2034; 100,000 options granted 02/28/2024 at $9.95 vesting 1/48 monthly after an initial one-year cliff; and 316,000 options granted 11/04/2024 at $10.27 with similar four-year vesting. All holdings are reported as direct ownership.
The filing is routine, conveys no operational or financial performance data, and does not imply the insider owns more than 10 % of outstanding shares.
FAQ
What is the current stock price of Ocular Therapeut (OCUL)?
What is the market cap of Ocular Therapeut (OCUL)?
What is Ocular Therapeutix's primary focus?
What is the significance of the proprietary ELUTYX technology?
Which products are showcased by the company?
How does Ocular Therapeutix address treatment challenges in ophthalmology?
What stages are the clinical trials in for the company’s pipeline?
How does the company ensure regulatory compliance?
What differentiates Ocular Therapeutix in the competitive biopharmaceutical market?
